Alexandre PUISSANT, Ph.D.

Research Scientist

CR2 Inserm

 

Team Leader

ATIP / Avenir

 

Affiliation

IUH Saint-Louis, Inserm U944

Paris, France

Phone: +331 53 72 40 63

Email: alexandre.puissant@inserm.fr



Alex Puissant is currently group leader of a young ATIP / AVENIR team created in January 2017 at the Institute of Hematology (IUH) at the Saint-Louis Hospital, in Paris (France).

 

After receiving his Ph.D. degree (2010) at the Mediterranean Center of Molecular Medecine (C3M) in Nice (France), Alex did his post-doctoral training at the Dana Farber Cancer Institute (DFCI/Harvard) in Boston (MA, USA), prior to joining Inserm in 2016.

 

His research is mainly focused on understanding mechanisms of progression and chemoresistance of a highly aggressive and deadly form of leukemia termed as Acute Myeloid Leukemias (AML). To do so, he has developed syngenic model of AML to set up screens using doxycycline-inducible shRNA libraries. He also performed long-term culture methods of primary leukemic blasts from patients with AML in order to identify cellular regulators of leukemic stem cell function.

 

 

Main Collaborations:

  • Kim Stegmaier DFCI (Boston, USA)
  • Mike Hemann Koch Institute (Cambridge, USA)
  • Ben Ebert − Brigham & Women's Hospital (Boston, USA)
  • Dirk Heckl Hannover Medical School (Hannover, Germany)
  • Eric Solary Gustave Roussy Intitute (Paris, France)
  • Mehdi Khaled Gustave Roussy Institute (Paris, France)
  • Camille Lobry − Gustave Roussy Institute (Paris, France)
  • Didier Bouscary/Jérôme Tamburini  Cochin Institute (Paris, France)
  • Patrick Auberger C3M (Nice, France)